Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Andorra Health Watch.
Press releases published on July 29, 2025
Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)
- Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges – - Potential expansion into Huntington’s chorea – an underserved indication with high need for long-acting VMAT2 therapy - HUNTSVILLE, …
Meliodays and Celanese Partner for Meliodays’ Development of Hormone-Free Non-Contraceptive IUD designed to Treat Menstrual Pain
Celanese’s VitalDose® Drug Delivery Platform will enable a long-acting, patient-centric formulation for Meliodays’ IUD design MUNICH, July 29, 2025 (GLOBE NEWSWIRE) -- Meliodays Medical and Celanese Corporation (NYSE: CE) have signed an agreement related …
MetrioPharm’s MP1032 Receives EMA Orphan Drug Designation in Duchenne Muscular Dystrophy
European Medicines Agency recognizes potential of lead compound MP1032 in addressing a high unmet medical need in Duchenne Muscular Dystrophy (DMD) Designation is paving the way for safer long-term therapy MP1032 has demonstrated ability to preserve muscle …
Concept Life Sciences & Fios Genomics Partner to Enhance Complex Data Analysis in Drug Discovery
CHAPEL-EN-LE-FRITH and EDINBURGH, United Kingdom, July 29, 2025 (GLOBE NEWSWIRE) -- Concept Life Sciences, a leading contract research organisation (CRO) serving the global life sciences industry, today announced a strategic partnership with Edinburgh- …
LIfT BioSciences announces grant of €12 million from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy
Galway, London, 29 July 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces a grant of €12 million has been awarded from Ireland’s Disruptive Technologies …
Basilea initiiert Phase-3-Studie mit Antipilzmittel Fosmanogepix bei invasiven Schimmelpilzinfektionen
Studie zur Evaluierung der Wirksamkeit und Sicherheit von Fosmanogepix bei Erwachsenen mit invasiven Schimmelpilzinfektionen Studienabschluss im 1. Quartal 2028 erwartet Allschwil, 29. Juli 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein …
Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections
Study to evaluate the efficacy and safety of fosmanogepix in adults with invasive mold infections Study completion expected in Q1 2028 Allschwil, Switzerland, July 29, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage …
Indonesia’s Ministry of Health and Philips to deliver nationwide coverage of advanced image-guided therapy systems in Indonesia, expanding access to cardiac, stroke and cancer care in all 38 provinces
July 29, 2025 Long-term multiyear agreements will see Philips installing its advanced Azurion image-guided therapy systems nationwide across all provinces, including rural and remote areas Initiative brings minimally invasive care to millions of cardiac, …
Philips builds strong order intake momentum and drives margin expansion in Q2
July 29, 2025 Q2 2025 Group Highlights Comparable order intake growth 6% Group sales EUR 4.3 billion, reflecting 1% increase in comparable sales Income from operations EUR 400 million Adjusted EBITA margin increased 130 bps to 12.4% of sales Free cash flow …